Latest news with #RenovaroInc
Yahoo
03-06-2025
- Business
- Yahoo
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions' (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling. 'This patent is a strategic milestone for Renovaro,' said David Weinstein, CEO of Renovaro. 'Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.' Key Drivers for Renovaro: Expands Foundational IP: Builds on core patent (US 11,379,757), granted in July 2022, which protects machine learning pipeline optimization through advanced feature selection and model tuning. Addresses Real-World Challenges: Tackles integration of siloed and heterogeneous data—an unmet need in pharmaceutical R&D and clinical practice. Enhances Commercial Potential: Enables scalable, distributed computing for biomedical analytics across use cases in rare disease, clinical trials, and personalized medicine. Supports Revenue Growth Strategy: Protects Renovaro's differentiated technology approach, critical for commercial partnerships, licensing opportunities, and platform deployment in life sciences and healthcare. The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies. This patent allowance reinforces Renovaro's commitment to building category-defining technology platforms that drive value for patients, partners, and shareholders alike. About Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking StatementsThis release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact: karen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger
Renovaro Inc. (NASDAQ:RENB) stated that the Delaware Court of Chancery has granted an expedited trial to its action against Predictive Oncology Inc. (NASDAQ:POAI), which was filed on May 9, 2025. A laboratory technician researching a sample of cells in a biotechnology laboratory. A binding merger agreement signed on January 1, 2025, which called for Predictive Oncology to merge into Renovaro Inc. (NASDAQ:RENB) in exchange for a new class of preferred stock, is being enforced in this action (No. 2025-0509). According to Renovaro's complaint, POAI violated the terms of exclusivity and good faith by launching a $545,000 public securities offering on February 19, 2025, and then making an attempt to unilaterally end the agreement on April 3, 2025. Renovaro Inc. (NASDAQ:RENB) is seeking damages, injunctive relief, and specific performance. The case focuses on a Letter Agreement that caused POAI's share price to rise by more than 50% and was made public in a January 6, 2025, Form 8-K. Renovaro Inc. (NASDAQ:RENB) asserts that POAI's activities, which breached the agreed-upon confidentiality and did not participate in substantive negotiations toward a final agreement, violated the conditions of the merger. Renovaro Inc. (NASDAQ:RENB) is a TechBio business that specializes in cancer treatments, drug development, and diagnostics. Among its subsidiaries are BioSymetrics (AI for precision neurology), RenovaroBio (cell-gene immunotherapy), and RenovaroCube (AI-driven diagnostics and drug development). Concerns about shareholder value and legal attempts to uphold M&A agreements are brought to light in this case. While we acknowledge the potential of RENB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RENB and that has 100x upside potential, check out our report about this READ NEXT: and .
Yahoo
23-05-2025
- Business
- Yahoo
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger
Renovaro Inc. (NASDAQ:RENB) stated that the Delaware Court of Chancery has granted an expedited trial to its action against Predictive Oncology Inc. (NASDAQ:POAI), which was filed on May 9, 2025. A laboratory technician researching a sample of cells in a biotechnology laboratory. A binding merger agreement signed on January 1, 2025, which called for Predictive Oncology to merge into Renovaro Inc. (NASDAQ:RENB) in exchange for a new class of preferred stock, is being enforced in this action (No. 2025-0509). According to Renovaro's complaint, POAI violated the terms of exclusivity and good faith by launching a $545,000 public securities offering on February 19, 2025, and then making an attempt to unilaterally end the agreement on April 3, 2025. Renovaro Inc. (NASDAQ:RENB) is seeking damages, injunctive relief, and specific performance. The case focuses on a Letter Agreement that caused POAI's share price to rise by more than 50% and was made public in a January 6, 2025, Form 8-K. Renovaro Inc. (NASDAQ:RENB) asserts that POAI's activities, which breached the agreed-upon confidentiality and did not participate in substantive negotiations toward a final agreement, violated the conditions of the merger. Renovaro Inc. (NASDAQ:RENB) is a TechBio business that specializes in cancer treatments, drug development, and diagnostics. Among its subsidiaries are BioSymetrics (AI for precision neurology), RenovaroBio (cell-gene immunotherapy), and RenovaroCube (AI-driven diagnostics and drug development). Concerns about shareholder value and legal attempts to uphold M&A agreements are brought to light in this case. While we acknowledge the potential of RENB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RENB and that has 100x upside potential, check out our report about this READ NEXT: and .
Yahoo
22-05-2025
- Business
- Yahoo
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following the public disclosure of the agreement in a Form 8-K filed by POAI on January 6, 2025, POAI's stock price rose by more than 50%. Renovaro alleges that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions by conducting a public offering of $545,000 in securities on February 19, 2025—despite contractual restrictions—and later attempting to terminate the agreement unilaterally on April 3, 2025, without engaging meaningfully in the negotiation of a definitive merger agreement. 'This transaction was intended to create strategic and shareholder value for both companies. Unfortunately, Predictive Oncology has disregarded its contractual commitments,' said a Renovaro spokesperson. 'We are pursuing legal remedies to enforce our rights and protect our shareholders' interests.' The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches. The case is pending in the Delaware Court of Chancery under Case No. 2025-0509. About Renovaro Inc. Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking Statements This release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact: karen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following the public disclosure of the agreement in a Form 8-K filed by POAI on January 6, 2025, POAI's stock price rose by more than 50%. Renovaro alleges that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions by conducting a public offering of $545,000 in securities on February 19, 2025—despite contractual restrictions—and later attempting to terminate the agreement unilaterally on April 3, 2025, without engaging meaningfully in the negotiation of a definitive merger agreement. 'This transaction was intended to create strategic and shareholder value for both companies. Unfortunately, Predictive Oncology has disregarded its contractual commitments,' said a Renovaro spokesperson. 'We are pursuing legal remedies to enforce our rights and protect our shareholders' interests.' The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches. The case is pending in the Delaware Court of Chancery under Case No. 2025-0509. About Renovaro Inc. Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking Statements This release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact: karen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
